ReviewFrontiers in immunology2016
Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 51 citations in OpenAlex.
- B1 Cells for Life.Immunological reviews · 2026Review
- Large-scale seroepidemiology uncovers nephro-urological pathologies in people with tau autoimmunity.PLoS biology · 2025Article
- The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Immunoglobulin: unraveling its complex web in aging.Frontiers in immunology · 2025Review
- The Spleen Modulates the Balance of Natural and Pathological Autoantibodies in a Mouse Model of Autoimmune Arthritis.International journal of molecular sciences · 2024Article
- The Emerging Role of Immunoglobulins and Complement in the Stimulation of Neuronal Activity and Repair: Not as Simple as We Thought.Biomolecules · 2024Review
- Levels of Natural Antibodies Before and After Immunoglobulin Replacement Treatment Affect the Clinical Phenotype in Common Variable Immunodeficiency.Journal of clinical immunology · 2024Article
- The immunology of B-1 cells: from development to aging.Immunity & ageing : I & A · 2024Review
- Human VH4-34 antibodies derived from B1 cells are more frequently autoreactive than VH4-34 antibodies derived from memory cells.Frontiers in immunology · 2023Article
- The Forgotten Brother: The Innate-like B1 Cell in Multiple Sclerosis.Biomedicines · 2022Review
- A tumor-associated autoantibody panel for the detection of non-small cell lung cancer.Frontiers in oncology · 2022Article
- Human B-1 cells are important contributors to the naturally-occurring IgM pool against the tumor-associated ganglioside Neu5GcGM3.Frontiers in immunology · 2022Article
- Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice.Aging cell · 2021Article
- Altered levels of circulating natural antibodies against VEGFR1-derived peptide in atherosclerosis.The Journal of international medical research · 2020Article
- Letter to the Editor: Importance of B cells in response to placental ischemia.American journal of physiology. Heart and circulatory physiology · 2020Article
- 2019 Russell Ross Memorial Lecture in Vascular Biology: B Lymphocyte-Mediated Protective Immunity in Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2020Article
- Current Understanding of Natural Antibodies and Exploring the Possibilities of Modulation Using Veterinary Models. A Review.Frontiers in immunology · 2020Review
- Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications.Frontiers in immunology · 2019Review
- Study of Novel Autoantibodies in Schizophrenia.Schizophrenia bulletin · 2018Article
- Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Natural antibodies are spontaneously produced in the absence of infection or immunization, and are both anti-microbial and autoreactive. Autoreactive natural antibodies can bind noxious molecules, such as those involved in clinical situations of atherosclerosis (oxLDL), malignancy (NGcGM3), and neurodegeneration (amyloid, tau) and can affect the fate of their targets or the cells bearing them to maintain homeostasis. Clinically relevant natural antibodies have been shown to decline with advancing age in those few situations where measurements have been made. Consistent with this, human B-1 cells that are thought to be responsible for generating natural antibodies also decline with advancing age. These findings together suggest that an age-related decline in amount or efficacy of homeostatic natural antibodies is associated with relative loss of protection against molecules involved in several diseases whose incidence rises in the older age population, and that those individuals experiencing greatest loss are at greatest risk. In this view, natural antibodies act as rheostats for susceptibility to several age-related diseases. These considerations suggest that administration of natural antibodies, or of factors that maintain B-1 cells and/or enhance production of natural antibodies by B-1 cells, may serve to counteract the onset or progression of age-related chronic illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.